Astellas Pharma (OTCMKTS:ALPMY) Shares Gap Up – Here’s Why

Shares of Astellas Pharma Inc. (OTCMKTS:ALPMY) gapped up before the market opened on Monday . The stock had previously closed at $13.21, but opened at $13.7999. Astellas Pharma shares last traded at $13.28, with a volume of 845 shares.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Jefferies Financial Group upgraded Astellas Pharma from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 24th. Zacks Research raised shares of Astellas Pharma from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, June 23rd. Two investment analysts have rated the stock with a Strong Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy”.

Astellas Pharma Trading Down 0.0%

The company has a 50 day simple moving average of $13.64 and a 200 day simple moving average of $14.64. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.90 and a current ratio of 1.17. The company has a market capitalization of $24.02 billion, a PE ratio of 12.36 and a beta of 0.07.

Astellas Pharma (OTCMKTS:ALPMY) last released its earnings results on Monday, April 27th. The company reported $0.33 earnings per share for the quarter, beating the consensus estimate of $0.19 by $0.14. The business had revenue of $3.38 billion for the quarter, compared to the consensus estimate of $3.28 billion. Astellas Pharma had a return on equity of 23.54% and a net margin of 13.66%. Analysts anticipate that Astellas Pharma Inc. will post 1.25 earnings per share for the current year.

About Astellas Pharma

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).